Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Candriam S.C.A.

Candriam S.C.A. lessened its stake in Guardant Health, Inc. (NASDAQ:GH) by 3.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 352,492 shares of the company’s stock after selling 13,653 shares during the period. Candriam S.C.A. owned about 0.29% of Guardant Health worth $10,769,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new stake in shares of Guardant Health during the 4th quarter worth $2,211,000. Arizona State Retirement System lifted its position in shares of Guardant Health by 1.1% in the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company’s stock valued at $1,089,000 after acquiring an additional 403 shares in the last quarter. Aigen Investment Management LP lifted its position in shares of Guardant Health by 35.9% in the fourth quarter. Aigen Investment Management LP now owns 25,957 shares of the company’s stock valued at $793,000 after acquiring an additional 6,854 shares in the last quarter. SWS Partners lifted its position in shares of Guardant Health by 44.3% in the fourth quarter. SWS Partners now owns 120,888 shares of the company’s stock valued at $3,693,000 after acquiring an additional 37,126 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Guardant Health by 1.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,016,533 shares of the company’s stock valued at $31,055,000 after acquiring an additional 13,395 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Raymond James restated an “outperform” rating and issued a $59.00 price objective (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Scotiabank upped their price objective on Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Monday, February 24th. Piper Sandler upped their price objective on Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. The Goldman Sachs Group upped their price objective on Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Finally, Barclays began coverage on Guardant Health in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 target price for the company. Twenty analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $48.40.

Insider Activity

In related news, Director Musa Tariq sold 2,320 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the transaction, the director now owns 2,676 shares of the company’s stock, valued at approximately $93,660. This represents a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last quarter, insiders sold 2,668 shares of company stock worth $95,208. 5.50% of the stock is currently owned by corporate insiders.

Guardant Health Stock Performance

GH stock opened at $39.32 on Friday. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $50.89. The firm has a market cap of $4.85 billion, a P/E ratio of -11.04 and a beta of 1.50. The stock has a 50-day simple moving average of $41.88 and a 200-day simple moving average of $32.32.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. On average, equities research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.